Introduction
============

The physiological principles of gas washout were first described more than 60 years ago and two different tests have been developed from them for clinical use: the single breath and the multiple gas washout techniques. It is said that these tests allow the detection of pulmonary ventilation inhomogeneity and also permit an estimate of the location of the underlying disease process.[@b1-copd-9-983]

Inert gases, such as helium (He), nitrogen (N~2~), and sulfur hexafluoride (SF~6~) have been used and the elimination curves that they produce during each expiration depict concentrations of the gas at different volumes until all the expiratory volume is expired. Irrespective of the gas used, all of the curves are the same and in each of them three phases can be identified: phase 1, with very low concentrations of the gas, which corresponds to the elimination of the air that is in the anatomic dead space; phase 2, generally a steep upward line, that represents the growing concentration of the gas that is eliminated from proximal alveolated air spaces; and phase 3, that is almost a plateau line and represents the elimination of the gas from most of the alveoli in the lungs.

The peripheral airways have been termed the silent lung zone because the conventional lung function tests are unable to detect their involvement in disease processes.

The phase 3 slope is an important feature of gas washout curves and contains information about gas transport in the alveolated airways of the lung periphery. It varies in many pathological conditions of the lungs.[@b2-copd-9-983]--[@b7-copd-9-983]

Volumetric capnography is a technique that analyzes the pattern of CO~2~ elimination as a function of expired volume. It produces a curve, the capnogram, that represents the total amount of CO~2~ eliminated by the lungs during each breath. As we would expect, the capnogram has the same form as the other gas elimination curves, with the advantage of being obtained with a gas that is normally produced in the body and eliminated by the lungs.[@b8-copd-9-983],[@b9-copd-9-983]

The objective of this study was to measure normalized phase 3 slopes with volumetric capnography in patients with non-cystic fibrosis bronchiectasis (NCB) and in patients with chronic obstructive pulmonary disease (COPD) with the bronchitic phenotype (cough, hypersecretion, wheezing) in order to compare the slopes obtained for the two groups.

Subjects and methods
====================

Our hospital (teaching hospital of the State University of Campinas) is a reference center for pulmonary diseases and we select for outpatient follow-up all the non-smoker patients with chronic sputum production and the smoker patients with the most severe manifestations of COPD (among other diseases not related to this study).

Twenty patients with NCB (NCB group) and 20 patients with COPD (Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] grade 3 and 4 of airflow limitation)[@b10-copd-9-983] with hypersecretion phenotype (chronic bronchitis \[CB\] group) were serially enrolled at the moment of their routine evaluation at our outpatient clinic. All patients who agreed to participate in the study were submitted to the pulmonary function tests (spirometry and volumetric capnography) and the 6-Minute Walk Test (6MWT) on the same day of their consultation.

A control group was established for the group of patients with bronchiectasis, paired by sex and age. These 20 subjects of the control group were volunteers who signed an informed consent form, and they all were nonsmokers, had no respiratory symptoms whatsoever, and no past or present history of lung disease. They all performed spirometry, volumetric capnography, and the 6MWT.

For the 6MWT, all patients were tested by the same technician under standardized conditions in accordance with the standards of the American Thoracic Society.[@b11-copd-9-983] Baseline blood pressure and heart rate were measured, and oxygen saturation (SpO~2~) was determined using a finger probe pulse oximeter (Nonin WristOx 3100™ (Nonin, Plymouth, MN, USA)). The pulse signal was carefully observed for at least 20 seconds, and the most frequent value on display, measured with a good pulse signal, was chosen. Saturation was measured at rest and immediately after the end of the 6-minute period, and the patients were carefully observed during the test to avoid dangerously exceeding their exercise limits. According to the American Thoracic Society guidelines,[@b11-copd-9-983] SpO~2~ should not be used for constant monitoring during the exercise and the technician must not walk with the patient to observe SpO~2~.

Desaturation was calculated as the resting oxygen saturation minus oxygen saturation after the 6-minute period. For the purpose of data analysis, a cut-off value for desaturation of 4% was chosen, which means a decrease in SpO~2~ from baseline \>4%. The 4% fall was validated in a study[@b12-copd-9-983] of exercise-induced hypoxemia during maximal exercise tests in athletes. Concerning the distance walked in the 6MWT, a cut-off of 400 m was chosen.

Pulmonary function tests were performed using a spirometer (Easy one-PC^®^; ndd, Switzerland) and the values of forced vital capacity (FVC), forced expiratory volume in the first second (FEV~1~), and FEV~1~/FVC ratio were analyzed. Reference values for the Brazilian population[@b13-copd-9-983] were used. FVC and FEV~1~ were expressed as a percent of the predicted value.

For the capnographic measurements, a CO~2~SMOS Plus 8100 Dixtal/Novametrix^®^ (Respironics, Murrisville, PA, USA) was used. The subjects remained breathing at tidal volume for a period of 4 minutes, during which time the variables were measured and the data were stored in the computer (software Analysis Plus^®^). At the end of data collection, an offline sequence of the respiratory cycles of the subjects was selected to accommodate a variation of \<15% for expiratory tidal volume and of \<5% for end-tidal concentration of CO~2~ (EtCO~2~) tension. The respiratory cycles, those presenting phase 3 slope values of zero, were excluded; for each of the measurements a mean value was determined.

The mean values of capnography, spirometry, and 6MWT for the three groups (NCB, BC, and controls) were determined. All subjects had their capnographic, spirometric, and variables of the 6MWT compared with the appropriate tests (Wilcoxon or Student's *t*-test); differences were considered significant with *P*\<0.05.

Approval for the use of patient data was obtained from the Research Ethics Committee of the Medical School of the State University of Campinas (UNICAMP).

Results
=======

Clinical data (age, sex, body mass index \[BMI\]) and functional data (spirometry, capnography, 6MWT) of subjects from the NCB group and the control group are shown in [Table 1](#t1-copd-9-983){ref-type="table"}. All patients in the NCB group and the control group were nonsmokers. Concerning clinical parameters, only BMI was different between the two groups, with higher values in the control group (*P*=0.022).

As for spirometric variables, determined after the use of bronchodilator, FEV~1~ (*P*\<0.0001), FVC (*P*\<0.0001) and FEV~1~/FVC ratio (*P*=0.011) were worse in NCB patients. The NCB group had FVC less than the lower limit of the range of predicted values more often than the control group (*P*\<0.0001) ([Figure 1](#f1-copd-9-983){ref-type="fig"}).

The mean 6MWT distance was lower in the bronchiectasis group compared with control group (*P*=0.006) and no significant drop in saturation happened at the end of the 6-minute walk in either group.

Regarding capnographic variables, mean expiratory tidal volume (Ve), mean expiratory volume normalized by weight in kilograms (Ve/kg), mean expiratory time (Te), mean minute volume (MV), mean airway dead space (VD/VT aw), mean peak expiratory flow (PEF), and mean EtCO~2~ were similar in the NCB and control groups. The mean inspiratory time was longer in the control group (*P*=0.028); the mean total respiratory rate (RR) was higher in patients with bronchiectasis. The mean Slp2 was lower in NCB patients (*P*=0.031); the mean phase 3 slope normalized by the mean expiratory volume (Slp3/Ve) or by the EtCO~2~ concentration (Slp3/EtCO~2~) was greater in NCB patients (*P*=0.0003 and *P*\<0.0001, respectively). The mean volume of CO~2~ eliminated during each breath was higher in the control group.

The comparison between the group of patients with bronchiectasis and the group of patients with severe COPD (GOLD 3 and 4) showed that bronchitic COPD patients were significantly older (*P*\<0.001), but the two groups had similar BMIs. The data of the groups are shown in [Table 2](#t2-copd-9-983){ref-type="table"}.

As for spirometric variables, patients with bronchiectasis (NCB group) had significantly better FEV~1~, FEV~1~/FVC, and PEF than the patients with chronic bronchitis COPD (COPD group) (*P*\<0.001, *P*\<0.0001, and *P*=0.002, respectively). Both groups had measurements of FVC below the lower limit of the expected value with high and similar frequency (90% for the NBC group, 95% for the COPD group) ([Figure 1](#f1-copd-9-983){ref-type="fig"}).

Eighty percent of bronchiectasis patients had an FEV~1~/FVC ratio greater than 0.7 and 95% of the patients with chronic bronchitis had it lower than 0.7 (*P*\<0.0001).

In the 6MWT, mean walk distance was lower in patients with chronic bronchitis (*P*=0.044), as well as the saturation before the test (*P*\<0.001). A fall of four or more percentage points at the end of the 6MWT was more frequent among patients with chronic bronchitis than among the subjects with bronchiectasis (*P*=0.029), as was the finding of a walk distance shorter than 400 m (*P*=0.027).

Regarding capnographic variables, Ve, Te, Ti, MV, RR, Ve/kg, V~D~/V~T~ aw, and PEF were similar in COPD and NCB groups. Also no significantly different values for Slp2, Slp3/Ve, and Slp3/EtCO~2~ were found. The EtCO~2~, VCO~2~/br, and VCO~2~ were significantly higher in COPD than in NCB patients (*P*=0.024, *P*=0.041, *P*=0.006, respectively) ([Figure 2](#f2-copd-9-983){ref-type="fig"}).

Discussion
==========

The analysis of the results of the comparison between the group of NCB patients and the control group, regarding the spirometric variables, shows that patients were significantly different from controls and had moderate obstructive disease with reduced FVC.

In the 6MWT, the NCB patients walked shorter distances than the controls, but the mean distance walked was greater than 400 m, a figure accepted as within normal limits.

In the capnographic measurements, the values of Slp2 (smaller), and of Slp3/Ve and Slp3/EtCO~2~ (greater), for the NCB group were significantly different from the control group. The Slp2 depicts the removal of CO~2~ from the alveoli, which are at the end of smaller airway paths. The branching of the bronchial tree, designed to fill the volume of the chest, allows the existence of paths of different lengths to the membrane for gas exchange; ie, to the alveoli. The more or less rapid rise in the concentration of CO~2~ in exhaled air at the end of the elimination of air from the anatomic dead space determines the slope of phase 2 of the volumetric capnogram and reflects the elimination of CO~2~ that comes from these shortest paths. Steeper slopes of phase 2 allow us to suppose that there are short branches of the bronchial tree occupying all spaces located within short distances from the central axis of the tree (the trachea). Therefore, normal individuals should have greater Slp2 than patients with lung diseases that reduce the number of these short paths. Phase 3 of the volumetric capnogram represents the elimination of CO~2~ from most of the alveoli and in normal individuals is almost a plateau, with a slight upward slope. The Slp3 should therefore be small. Increases in Slp3 happen in situations of heterogeneous involvement of the distal air spaces, which lead to heterogeneous distribution of the air in these regions and reduced area of contact between the CO~2~ that crosses the alveolar--capillary membrane and the renewed air that arrived in the previous inspiration. Larger values of Slp3/Ve and Slp3/EtCO~2~ in patients suggest the existence of structural damage to the peripheral lung, which promotes this heterogeneous distribution of ventilation.[@b2-copd-9-983],[@b3-copd-9-983]

The comparison between the NCB group and the group of patients with COPD GOLD 3 and 4 revealed that individuals with COPD had much worse spirometric values, walked less than 400 m, and desaturated four or more percentage points with a significantly higher frequency than patients with bronchiectasis ([Table 2](#t2-copd-9-983){ref-type="table"}).

Spirometry and the 6MWT were able to demonstrate that individuals with COPD had worse disease than patients with bronchiectasis. However, the capnographic variables Slp2, Slp3/Ve, and Slp3/EtCO~2~ were similar in both groups.

These findings may show that capnography is not able to differentiate between the different types of structural disease shown by these groups, and is not sensitive to the worse clinical condition of the COPD patients.

It is very difficult to monitor the progression of structural abnormalities in both diseases (NCB and COPD) and this was not a longitudinal study, so making statements about progression is not appropriate.

Cosio et al,[@b14-copd-9-983] in a fundamental study published in 1978, demonstrated that structural changes in small airways of susceptible smokers with smoking histories greater than 35 pack-years could be reflected in the nitrogen single-breath washout test. Increasing pathology scores (that included evaluation of inflammatory cell infiltrate, squamous cell metaplasia of the airway epithelium, and airway wall fibrosis) of the small airways (\<2 mm internal diameter) were accompanied by increasing ventilation heterogeneity as measured from the N~2~ phase 3 slope of the single-breath washout test. This test of unevenness of ventilation could detect structural changes in the small airways of smokers long before spirometry could. But this measurement produced deceiving results in predicting decline of FEV~1~[@b15-copd-9-983],[@b16-copd-9-983] and these data agree with the findings in this study.

The pattern of decreasing or increasing gas concentrations during the multiple-breath washout tests has the potential to anatomically locate the affected small airways in acinar and conductive lung zones through increased phase 3 slope indices S~acin~ (acinar lung zone) and S~cond~ (conductive lung zone).[@b17-copd-9-983] These calculations allowed the determination of the relative contribution of conductive and acinar airspaces in diseases such as asthma,[@b18-copd-9-983] cystic fibrosis,[@b19-copd-9-983] and COPD,[@b20-copd-9-983] and in conditions such as aging.[@b21-copd-9-983]

In volumetric capnography, CO~2~ concentration is analyzed during multiple breaths, on average more than 50 breaths, but the pattern of elimination for an individual shows small variations from breath to breath due to the steady supply of CO~2~ to the lungs. This aspect of volumetric capnography probably makes it less informative than the classical, sophisticated, and more expensive multiple-breath washout tests.

Nevertheless, perhaps the natural histories of both diseases evaluated here have differences that justify the findings of the present study. Chronic bronchitis associated with smoking is caused by the toxic action of many substances produced by burning tobacco that are repeatedly inhaled by the smokers. Generally all smokers have a productive cough, at least in the morning soon after waking up; however, not all smokers will have airflow obstruction on spirometry. Those individuals who develop obstructive disease are characterized as COPD patients. The airflow obstruction in COPD happens when there are structural changes in small airways and/or alveoli.[@b22-copd-9-983],[@b23-copd-9-983] Apparently, all smokers have proximal airway injury, but only a variable percentage also have peripheral structural lesions.[@b10-copd-9-983]

Patients with severe COPD thus have proximal and distal changes in the airways that are sequential or almost simultaneous, but may certainly occur earlier in the proximal airways. The reason why only a few smokers develop COPD is still unknown. However, it can be speculated that the structure of the bronchial tree may be one of many factors that favor the onset of the disease. Simplification of the bronchial tree branching, either congenital or acquired in the postnatal period as a result of an infection in childhood, may facilitate the action of toxic substances from cigarettes, allowing them to reach further down the airways.

Bronchiectasis appears to have a different natural history. The initial lesion in bronchiectasis most likely occurs in the small airways (bronchioles of less than 2 mm in diameter). Evidence supporting this hypothesis is available for cystic fibrosis, a disease that progresses with extensive dilation of central bronchi. Before bronchiectasis appears, clear signs of small airways disease are detectable by lung function evaluation and imaging studies such as a computed tomography (CT) scan of the chest.[@b24-copd-9-983] In cystic fibrosis, the mucociliary transport is severely compromised by the reduced amount of water in the periciliary liquid.[@b25-copd-9-983]--[@b27-copd-9-983]

In ciliary dyskinesia, a disease that also causes dilation of the central bronchi, CT signs of bronchiolitis, especially the pattern described as "tree-in-bud" on high-resolution CT scans of the chest, are very often found in areas of the lung without dilated central bronchi. The loss of cilia beating in subjects with ciliary dyskinesia decreases the efficiency of mucociliary transport, a situation that seems to be common to many of the diseases that cause bronchiolitis/bronchiectasis.[@b26-copd-9-983]

Again, the structure explains the importance of lung mucociliary transport for the removal of secretions in the small airways. Bronchial branching does significantly increase the cross-sectional area of the distal airspaces. The movement of gases by pressure (convection), which generates airflow, happens to some extent in the airways. The increased cross-sectional area in the distal air spaces causes airflow to drop dramatically. Failure to maintain adequate flow interferes with the ability to generate effective cough. Without cough, elimination of respiratory secretions, that trap biological and non-biological particles and many diluted or cross-linked toxic substances, is entirely dependent on mucociliary transport.[@b28-copd-9-983]

In idiopathic bronchiectasis, although the causative mechanism of mucociliary transport impairment is unknown, the presence of tomographic signs of bronchiolitis in lung regions where dilatation of the central bronchi are not yet detected has been demonstrated; other areas show both bronchiolitis and bronchiectasis.[@b29-copd-9-983]

In 1950, Reid[@b30-copd-9-983] published a cornerstone study on the pathology of extensive bronchiectasis, whose conclusions cleared many intriguing aspects of this condition. One of the most important findings was the reduction of bronchial subdivisions between the hilum and the periphery of the lung, especially in the saccular type of bronchiectasis. The missing bronchi, whenever their remnants could be identified, were obliterated by fibrous tissue and all the generations of bronchi and small airways that should arise from them had completely disappeared.

The combination of these findings with the visualization of signs of small airway disease on high-resolution CT scans of the chest (air trapping and/or tree-in-bud) allow us to hypothesize that in diffuse bronchiectasis the most important and probably most initial lesions occur in the small airways of less than 2 mm in diameter because their dependence on mucociliary clearance and other airway defense mechanisms is much greater than in central airways. The accelerated and heterogeneous loss of small airways, through inflammation and fibrous obliteration, may lead to a highly variable distribution of gases in the distal air spaces and a reduction in the area of contact between the gas in the alveoli and the new gas that arrives at each inspiration.

These lesions may happen earlier and be more intense in conditions that cause diffuse bronchiectasis than in COPD patients and the slope of phase 3 in the volumetric capnogram and other single-breath washout curves could be specially suited to detect them.

Dutrieue et al,[@b31-copd-9-983] in their work published in 2000, demonstrated that the phase 3 slope, which is generally referred to as a marker of small airway alterations, showed great sensitivity to intra-acinar asymmetry, which can be a property of the acinus related to the asymmetric branching pattern of the airways or may be produced or aggravated by disease conditions that affect distal airspaces.

The lung clearance index (LCI), derived from the concentration curves obtained during a multiple-breath washout and used to quantify the inefficiency in gas mixing in the lungs, has been considered a valuable tool for early detection of lung structure alterations in children with cystic fibrosis.[@b1-copd-9-983],[@b32-copd-9-983],[@b33-copd-9-983]

But Verbanck et al,[@b34-copd-9-983] in their work published in 2012, concluded that although LCI can potentially be affected by a structural change in the small airways, it can be modified likewise by structural changes in more proximal airways. In addition, a simple increase in anatomical dead space (common in bronchiectasis patients) leads to an LCI increase. Hence, LCI is not a small airway test in the sense that any observed change in LCI cannot be readily interpreted as the unequivocal reflection of a structural alteration of the small airways.

The role of normalized phase 3 slope may be worth exploring as a more sensitive index of small airway disease, even though it may not be equally sensitive in discriminating the severity of the alterations. Volumetric capnography may be an easier and less expensive way of measuring phase 3 slopes in a significant number of chronic lung diseases.
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![Comparison between mean values of spirometric parameters of the three groups: control, NCB, and COPD (FEV~1~ and FVC shown as percentage predicted value).\
**Notes:** \**P*\<0.0001; \*\**P*=0.01; ^†^*P*\<0.05.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in the first second; FVC, forced vital capacity; NCB, non-cystic fibrosis bronchiectasis.](copd-9-983Fig1){#f1-copd-9-983}

![Curves of volumetric capnography of control (**A**), bronchiectasis (**B**), and COPD (**C**) groups (representative curves).\
**Notes:** (**A**) EtCO~2~ =35.1 mmHg; Ve =590 mL; Slope 3=11.17 mmHg/L. (**B**): EtCO~2~ =32.9 mmHg; Ve =502 mL; Slope 3=32.05 mmHg/L. (**C**) EtCO~2~ =36.8 mmHg; Ve =589 mL; Slope 3=34.10 mmHg/L.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; EtCO~2~, end-tidal CO~2~.](copd-9-983Fig2){#f2-copd-9-983}

###### 

Comparison between patients with NCB and control group

  -------------------------------------------------------------------------------------------------------------
                         NCB\          Control group\   *P*
                         (N=20)        (N=20)           
  ---------------------- ------------- ---------------- -------------------------------------------------------
  Age (years)            48.3±18.4     47.1±16.6        0.823[\*\*](#tfn3-copd-9-983){ref-type="table-fn"}

  BMI (Kg/m^2^)          23.1±4.7      25.4±2.7         0.022[\*](#tfn2-copd-9-983){ref-type="table-fn"}

  FEV~1~ (% predicted)   56.5±18.4     99.3±19.6        \<0.0001[\*\*](#tfn3-copd-9-983){ref-type="table-fn"}

  FVC (% predicted)      64.6±13.1     97.5±18.7        \<0.0001[\*\*](#tfn3-copd-9-983){ref-type="table-fn"}

  FEV~1~/FVC             70.4±14.6     81.9±14.6        0.011[\*](#tfn2-copd-9-983){ref-type="table-fn"}

  PEF (% predicted)      51.3±14.6     58.7±36.6        0.245[\*](#tfn2-copd-9-983){ref-type="table-fn"}

  6MWD (m)               445.7±159.9   538.9±90.8       0.006[\*](#tfn2-copd-9-983){ref-type="table-fn"}

  Δ saturation (%)       −0.4±1.6      0.9±1.1          0.001[\*\*](#tfn3-copd-9-983){ref-type="table-fn"}

  Ve (mL)                502.0±150.0   589.5±150.0      0.120[\*\*](#tfn3-copd-9-983){ref-type="table-fn"}

  Te (s)                 2.3±0.5       2.8±0.5          0.060[\*](#tfn2-copd-9-983){ref-type="table-fn"}

  Ti (s)                 1.5±0.4       1.8±0.4          0.027[\*\*](#tfn3-copd-9-983){ref-type="table-fn"}

  Slope 2 (mmHg/L)       257.7±109.3   332.0±100.6      0.031[\*\*](#tfn3-copd-9-983){ref-type="table-fn"}

  Slope 3/Ve             0.07±0.06     0.02±0.06        \<0.001[\*](#tfn2-copd-9-983){ref-type="table-fn"}

  Slope 3/EtCO~2~        0.9±0.4       0.3±0.1          \<0.0001[\*](#tfn2-copd-9-983){ref-type="table-fn"}

  MV (L)                 8.0±2.1       7.6±2.1          0.607[\*\*](#tfn3-copd-9-983){ref-type="table-fn"}

  RR (cicles/m)          16.5±3.4      13.8±4.1         0.033[\*\*](#tfn3-copd-9-983){ref-type="table-fn"}

  Ve (mL/Kg)             8.6±2.7       8.4±2.3          0.798[\*\*](#tfn3-copd-9-983){ref-type="table-fn"}

  Vd/Vt aw               0.30±0.08     0.26±0.06        0.072[\*\*](#tfn3-copd-9-983){ref-type="table-fn"}

  EtCO~2~                32.9±5.2      35.1±4.3         0.157[\*\*](#tfn3-copd-9-983){ref-type="table-fn"}

  VCO~2~/br              10.2±3.5      15.5±6.8         0.008[\*](#tfn2-copd-9-983){ref-type="table-fn"}

  VCO~2~ (mL/m)          157.5±8.3     192.6±10.6       0.013[\*\*](#tfn3-copd-9-983){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------------------

**Notes:** All spirometric measurements (FVC, FEV~1~, and PEF) correspond to the values obtained after the use of bronchodilator.

Mann--Whitney test;

Student's *t*-test; values expressed in mean ± SD; *P*\<0.05 was considered to be a statistically significant difference.

**Abbreviations:** 6MWD, walked distance in the 6-minute walk test; Δ saturation, difference between baseline pulse saturation and saturation at the final of the 6-minute walk test; BMI, body mass index; EtCO~2~, end-tidal CO~2~; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; MV, quantity of air inhaled expressed in terms of volume per minute; NCB, non-cystic fibrosis bronchiectasis; PEF, peak of expiratory flow; RR, respiratory rate; SD, standard deviation; Slope 3/EtCO~2~, slope 3 normalized by end-tidal CO~2~; Slope 3/VT, slope 3 normalized by tidal volume; Te, duration of the expiratory phase; Ti, duration of the inspiratory phase; VCO~2~, the volume of CO~2~ produced; VCO~2~/br, excretion of CO~2~ per breath; Vd/Vt aw, deadspace volume by tidal volume ratio; Ve, expired tidal volume.

###### 

Comparison between patients with NCB and COPD patients

  ---------------------------------------------------------------------------------------------------------
  Variable               NCB\          COPD\        *P*-value
                         (N=20)        (N=20)       
  ---------------------- ------------- ------------ -------------------------------------------------------
  Age (years)            48.3±18.4     65.7±7.4     \<0.001[\*](#tfn6-copd-9-983){ref-type="table-fn"}

  BMI (Kg/m^2^)          23.1±4.7      25.0±6.2     0.278[\*\*](#tfn7-copd-9-983){ref-type="table-fn"}

  FVC (% predicted)      64.6±13.1     56.8±12.2    0.059[\*\*](#tfn7-copd-9-983){ref-type="table-fn"}

  FEV~1~ (% predicted)   56.5±18.4     36.9±12.3    \<0.001[\*\*](#tfn7-copd-9-983){ref-type="table-fn"}

  FEV~1~/FVC             70.4±14.6     50.4±10.3    \<0.0001[\*\*](#tfn7-copd-9-983){ref-type="table-fn"}

  PEF (% predicted)      51.3±19.8     32.6±14.1    0.002[\*\*](#tfn7-copd-9-983){ref-type="table-fn"}

  SpO~2~ (%)             96.1±2.6      92.3±1.8     \<0.0001[\*\*](#tfn7-copd-9-983){ref-type="table-fn"}

  6MWD (m)               445.7±159.9   353.8±88.2   0.044[\*](#tfn6-copd-9-983){ref-type="table-fn"}

  Δ saturation (%)       −0.4±1.6      −2.4±1.9     \<0.001[\*](#tfn6-copd-9-983){ref-type="table-fn"}

  Slope 2 (mmHg/L)       257.7±109.3   235.5±93.2   0.493[\*\*](#tfn7-copd-9-983){ref-type="table-fn"}

  Slope 3/Ve             0.08±0.06     0.07±0.05    0.749[\*\*](#tfn7-copd-9-983){ref-type="table-fn"}

  Slope 3/EtCO~2~        0.93±0.46     0.94±0.33    0.992[\*\*](#tfn7-copd-9-983){ref-type="table-fn"}
  ---------------------------------------------------------------------------------------------------------

**Notes:** All spirometric measurements (FVC, FEV~1~, and PEF) correspond to the values obtained after the use of bronchodilator.

Mann--Whitney test;

Student's *t*-test; values expressed in mean ± SD; *P*\<0.05 was considered to be a statistically significant difference.

**Abbreviations:** 6MWD, walked distance in the 6-minute walk test; Δ saturation, difference between baseline pulse saturation and saturation at the final of the 6-minute walk test; BMI, body mass index; COPD, chronic obstructive pulmonary disease; EtCO~2~, end-tidal CO~2~; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; NCB, non-cystic fibrosis bronchiectasis; PEF, peak of expiratory flow (L/second); SD, standard deviation; Slope 3/EtCO~2~, slope 3 normalized by EtCO~2~; Slope 3/Ve, slope 3 normalized by expired tidal volume; SpO~2~, oxygen saturation.
